文献速递运动医学关节外科

全软组织股四头肌腱自体移植物在运动员翻修前交叉韧带重建中的应用:与骨-髌腱-骨自体移植物至少2年随访的比较

All-Soft Tissue Quadriceps Tendon Autograft in Revision Anterior Cruciate Ligament Reconstruction in Athletes: Comparison to Bone-Patellar Tendon-Bone Autograft With at Least a 2-Year Follow-up.
PubMed 文献 · Am J Sports Med · 2022-10-26

回顾性队列研究比较运动员翻修前交叉韧带重建中全软组织股四头肌腱(ASTQT)与骨-髌腱-骨(BTB)自体移植物的疗效。共纳入58例(ASTQT组32例,BTB组26例),随访至少2年。ASTQT组重返运动更快(8.9 vs 10.3个月,P=0.020),6个月和12个月IKDC及Lysholm评分更高,但最终随访时两组评分无显著差异,再撕裂率和其他并发症无差异。结论认为ASTQT是翻修前交叉韧带重建中可行的移植物选择。

要点

  • ASTQT组重返运动时间显著短于BTB组(8.9 vs 10.3个月,P=0.020)。
  • 6个月和12个月IKDC及Lysholm评分ASTQT组显著更高,但最终随访时两组无显著差异。
  • 再撕裂率和其他并发症两组无差异,ASTQT可考虑作为翻修ACL重建的可行移植物选择。

核心结论

  • 在运动员翻修前交叉韧带重建中,ASTQT自体移植物与BTB自体移植物相比具有相似的结果。
  • ASTQT可能提供更快的重返运动和更好的患者报告结局早期改善,这些改善在1年时趋于一致。
  • 作者认为软组织股四头肌自体移植物应被视为翻修前交叉韧带重建中可行的移植物选择。

研究设计与样本

  • 回顾性队列研究,证据等级3级。
  • 纳入2013年8月至2019年12月在一家机构接受翻修前交叉韧带重建的运动员,参与高中或大学体育运动,首次翻修,使用ASTQT或BTB自体移植物,随访至少2年。
  • 共纳入58例翻修前交叉韧带重建,ASTQT组32例,BTB组26例。

主要发现

  • 同水平重返运动:ASTQT组62.5%,BTB组53.8%。
  • 重返运动时间:ASTQT组8.9个月 vs BTB组10.3个月(P=0.020),ASTQT组显著更快。
  • 再撕裂率:ASTQT组3.1% vs BTB组7.7%,两组间无差异;其他并发症两组间无差异。
  • IKDC评分:6个月时ASTQT组71.3 vs BTB组61.7(P=0.001);12个月时ASTQT组82.7 vs BTB组78.6(P=0.021),ASTQT组显著更高。
  • Lysholm评分:6个月时ASTQT组75.1 vs BTB组63.6(P<0.001);12个月时ASTQT组82.0 vs BTB组74.5(P<0.001),ASTQT组显著更高。

临床怎么用

  • 作者认为软组织股四头肌自体移植物应被视为运动员翻修前交叉韧带重建中可行的移植物选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Revision anterior cruciate ligament (ACL) reconstruction is being performed at an increasing rate. Previous literature has suggested that autograft ACL reconstruction is a better option than allograft in revision surgery, although the optimal autograft choice remains unknown. The all-soft tissue quadriceps tendon (ASTQT) autograft has been found to be an effective option for primary ACL reconstruction. However, few studies have evaluated ASTQT autograft in revision ACL reconstruction. PURPOSE/HYPOTHESIS: The purpose of this study was to evaluate the ASTQT autograft in revision ACL reconstruction in athletes compared with bone-patellar tendon-bone (BTB) autograft. We hypothesized that the ASTQT autograft would lead to similar return to play, time to return to play, retear rate, and patient-reported outcomes compared with BTB autograft. STUDY DESIGN: Cohort study; Level of evidence, 3. METHODS: A retrospective study was performed on all athletes undergoing revision ACL reconstruction between August 2013 and December 2019 at a single institution. Patients participating in high school or college athletics undergoing first-time revision with either ASTQT or BTB autograft with ≥2 years of follow-up were included. Demographic variables, complications, return to sports, and outcome scores including the International Knee Documentation Committee (IKDC) and Lysholm were collected and compared between the 2 cohorts. RESULTS: A total of 58 revision ACL reconstructions were included, with 32 in the ASTQT cohort and 26 in the BTB cohort. Return to sports at the same level occurred in 62.5% of the ASTQT group and 53.8% of the BTB group. The ASTQT group returned to sports significantly faster than the BTB group (8.9 vs 10.3 months; P = .020). There was no difference in retear rates (3.1%, ASTQT; 7.7%, BTB) or other complications between the 2 groups. The IKDC scores were significantly higher at the 6- and 12-month follow-up for the ASTQT autograft group compared with the BTB group (6 months: ASTQT, 71.3; BTB, 61.7, P = .001; 12 months: ASTQT, 82.7; BTB, 78.6; P = .021). Lysholm scores were also greater in the ASTQT cohort at these time points (6 months: ASTQT, 75.1; BTB, 63.6; P < .001; 12 months: ASTQT, 82.0; BTB, 74.5; P < .001). However, IKDC and Lysholm scores were similar between both groups at final follow-up (IKDC: ASTQT, 82.9; BTB, 81.7; P = .344; Lysholm: ASTQT, 83.0; BTB, 81.0; P = .104) There was no significant clinical difference in the absolute difference in scores or rate of achieving clinical thresholds between the 2 cohorts. CONCLUSION: ASTQT autograft for revision ACL in athletes has similar outcomes compared with BTB autograft. However, the ASTQT may possibly afford quicker return to sports and better early improvements in patient-reported outcomes that normalize by 1 year. The soft tissue quadriceps autograft should be considered a viable graft option in revision ACL reconstruction in athletes.

来源:Am J Sports Med,查看原文。版权归原作者所有。

引用

  1. Brinkman JC, Tummala SV, Moore ML, et al. All-Soft Tissue Quadriceps Tendon Autograft in Revision Anterior Cruciate Ligament Reconstruction in Athletes: Comparison to Bone-Patellar Tendon-Bone Autograft With at Least a 2-Year Follow-up. Am J Sports Med. 2022. PMID: 36285655. doi:10.1177/03635465221126523

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。